Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.80 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 6/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.61 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | CA2 | P00918 | 3/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzylhydrochlorothiazide SCHEMBL49671 | 0.89 | ALDH1A1 (1.00) | ALDH1A1CYP1A2L3MBTL1TDP1LMNA | |
| Benzylhydrochlorothiazide SCHEMBL18314134 | 0.89 | ALDH1A1 (1.00) | ALDH1A1CYP1A2L3MBTL1TDP1LMNA | |
| SCHEMBL13685945 | 0.81 | TDP1 (0.79) | ALDH1A1CYP1A2L3MBTL1TDP1LMNA | |
| Ethiazide SCHEMBL30561875 | 0.80 | TDP1 (1.00) | ALDH1A1CYP1A2L3MBTL1TDP1LMNA | |
| Ethiazide SCHEMBL122238 | 0.80 | TDP1 (1.00) | ALDH1A1CYP1A2L3MBTL1TDP1LMNA | |
| SCHEMBL11038368 | 0.80 | TDP1 (0.77) | ALDH1A1CYP1A2L3MBTL1TDP1LMNA | |
| SCHEMBL29925887 | 0.78 | TDP1 (0.82) | ALDH1A1CYP1A2L3MBTL1TDP1LMNA | |
| SCHEMBL18309810 | 0.78 | ALDH1A1 (0.80) | ALDH1A1CYP1A2L3MBTL1TDP1LMNA | |
| Buthiazide SCHEMBL309110 | 0.77 | TDP1 (0.76) | ALDH1A1CYP1A2L3MBTL1TDP1LMNA | |
| SCHEMBL7366786 | 0.77 | TDP1 (0.72) | ALDH1A1CYP1A2L3MBTL1TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1387 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170079978-A1 | THERAPY FOR COMPLICATIONS OF DIABETES | ABBVIE DEUTSCHLAND (DE) | 2017-03-23 | — | — | US | claimed |
| CN-102552161-B | The preparation method of a kind of pharmaceutical solid preparation and gained pharmaceutical solid preparation | 上海中西制药有限公司 | 2016-06-22 | — | — | CN | claimed |
| CN-105640890-A | Sparingly soluble active component particle, particle preparation and preparation method thereof | 华东理工大学 | 2016-06-08 | — | — | CN | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8865650-B2 | Therapy for complications of diabetes | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-10-21 | — | — | US | claimed |
| US-20140073574-A1 | THERAPY FOR COMPLICATIONS OF DIABETES | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-03-13 | — | — | US | claimed |
| US-8623819-B2 | Therapy for complications of diabetes | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-01-07 | — | — | US | claimed |
| US-20130178424-A1 | THERAPY FOR COMPLICATIONS OF DIABETES | AbbVie Deutschland GmbH & Co. KG (DE) | 2013-07-11 | — | — | US | claimed |
| EP-2560634-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | Piramal Enterprises Limited (IN) | 2013-02-27 | — | — | EP | claimed |
| CN-102552161-A | Preparation method of medicament solid preparation and obtained medicament solid preparation | SHANGHAI ZHONGXI PHARMACEUTICAL CO LTD | 2012-07-11 | — | — | CN | claimed |
| EP-1507813-A1 | FAT BINDING USING INTER-POLYMER COMPLEX OF GLUCOSAMINE AND POLYACRYLIC ACID | Ranbaxy Laboratories Limited (IN) | 2005-02-23 | — | — | EP | claimed |
| EP-1087953-B1 | NITRATE SALTS OF ANTIHYPERTENSIVE MEDICINES | NICOX SA (FR) | 2004-11-17 | — | — | EP | claimed |
| EP-1385501-A2 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | Atherogenics, Inc. (US) | 2004-02-04 | — | — | EP | claimed |
| WO-2003097714-A1 | FAT BINDING USING INTER-POLYMER COMPLEX OF GLUCOSAMINE AND POLYACRYLIC ACID | RANBAXY LABORATORIES LIMITED (IN) | 2003-11-27 | — | — | WO | claimed |
| US-20030162824-A1 | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor | PHARMACIA CORPORATION | 2003-08-28 | — | — | US | claimed |
| WO-2002087556-A9 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS INC (US) | 2003-03-20 | — | — | WO | claimed |
| WO-2002087556-A2 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS, INC. (US) | 2002-11-07 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073574-A1 | THERAPY FOR COMPLICATIONS OF DIABETES | EDNRA, EDNRB, GPR119 | ALDH1A1 3889/4885CYP1A2 3181/4885L3MBTL1 2802/4885 |
| US-20030162824-A1 | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor | PTGS1, PTGIS, TNNT2 | ALDH1A1 515/4885CYP1A2 477/4885L3MBTL1 3256/4885 |
| US-20170079978-A1 | THERAPY FOR COMPLICATIONS OF DIABETES | EDNRA, EDNRB, GPR119 | ALDH1A1 3904/4885CYP1A2 3189/4885L3MBTL1 2812/4885 |
| US-20130178424-A1 | THERAPY FOR COMPLICATIONS OF DIABETES | EDNRA, EDNRB, GPR119 | ALDH1A1 3889/4885CYP1A2 3181/4885L3MBTL1 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.